To examine the efficacy and safety of photodynamic therapy with verteporfinin the treatment of subfoveal choroidal neovascularization secondary to centralserous chorioretinopathy (CSC).
Prospective interventional, noncomparative case series.
After the diagnosis of a subfoveal choroidal neovascularization secondaryto CSC, 26 eyes of 24 patients were treated with photodynamic therapy withverteporfin. Patients were then followed up every 2 to 3 months, with furthertreatments performed as deemed necessary through fluorescein angiography.The mean observation was 22.2 months (range, 6-36 months; median, 24 months).
There was marked visual improvement, with patients gaining a mean of1.6 lines after 1 year and a mean of 2.2 lines after 2 years. There was astatistically significant change in visual acuity from baseline to 12 and24 months (mean difference, –0.16, P = .03;and mean difference, –0.22, P = .02; respectively; t test for both). There was no correlation between patients'age or greatest linear dimension of the lesions and the final outcome (P>.10 for all). No patient experienced any adverse effects.
Photodynamic therapy with verteporfin resulted in a beneficial outcomein the treatment of subfoveal choroidal neovascularization secondary to CSC,without serious adverse effects in this case series.